Psych Pipeline

CNS compounds in development, with mechanism, phase, and trial evidence. Early preview.

• AEF0117 (lixosicone)Phase 2
  Cannabis use disorder· CB1 NAM· Aelis Farma S.A.
• AEF0217Phase 2
  Down Syndrome· CB1 NAM· Aelis Farma S.A.
• AlixorextonPhase 3
  Narcolepsy· OX2R Agonist· Alkermes plc
• ALTO-100 (amdiglurax)Phase 2
  Bipolar depression· TLX Agonist· Alto Neuroscience, Inc.
• ALTO-101Discontinued
  Schizophrenia· Phosphodiesterase 4 Inhibitor· Alto Neuroscience, Inc.
• ALTO-203Phase 2
  Major depressive disorder· H3 receptor Inverse agonist· Alto Neuroscience, Inc.
• ALTO-207Phase 2
  Treatment-resistant depression· D3 Agonist· Alto Neuroscience, Inc.
• ALTO-300 (agomelatine)Phase 2
  Major depressive disorder· MT1 Agonist· Alto Neuroscience, Inc.
• Ammoxetine (S-071031B)Phase 3
  Major depressive disorder· Serotonin transporter (SERT) Inhibitor· CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.
• Apimostinel (GATE-202)Phase 2
  Major depressive disorder· GluN2B PAM· Syndeio Biosciences, Inc.
• AticaprantDiscontinued
  Major depressive disorder· KOR Antagonist· Johnson & Johnson
• Atuzaginstat (COR388)Discontinued
  Alzheimer's disease· Kgp Inhibitor· Cortexyme, Inc. (now Quince Therapeutics, Inc.)
• AXS-05 (dextromethorphan-bupropion)Approved
  Agitation in Alzheimer's disease· NMDA receptor Antagonist· Axsome Therapeutics, Inc.
• AXS-12 (reboxetine)Filed (NDA)
  Narcolepsy· NET Reuptake inhibitor· Axsome Therapeutics, Inc.
• AXS-14 (esreboxetine)Phase 3
  Fibromyalgia· NET Reuptake inhibitor· Axsome Therapeutics, Inc.
• Azetukalner (XEN1101)Phase 3
  Epilepsy· Kv7.2 Activator· Xenon Pharmaceuticals Inc.
• BHV-2100Phase 2
  Migraine· TRPM3 Antagonist· Biohaven Ltd.
• BHV-8000Phase 2/3
  Parkinson's disease· TYK2 Inhibitor· Biohaven Ltd.
• BI 1358894Discontinued
  Major depressive disorder· TRPC4 Inhibitor· Boehringer Ingelheim International GmbH
• BI 1569912Phase 2
  Major depressive disorder· GluN2B NAM· Boehringer Ingelheim International GmbH
• Blixeprodil (GM-1020)Phase 2
  Major depressive disorder· NMDA receptor Antagonist· Gilgamesh Pharmaceuticals, Inc.
• BNC210 (soclenicant)Phase 2
  Post-traumatic stress disorder· alpha7 nAChR NAM· Neuphoria Therapeutics, Inc.
• BPL-003 (intranasal 5-MeO-DMT benzoate)Phase 2
  Treatment-resistant depression· 5-HT1A Agonist· Beckley Psytech Limited
• Bretisilocin (GM-2505)Phase 2
  Major depressive disorder· 5-HT2A Agonist· Gilgamesh Pharmaceuticals, Inc.
• BrexpiprazoleFiled (NDA)
  Post-traumatic stress disorder· D2 Partial agonist· Otsuka Pharmaceutical Co., Ltd.
• Brezivaptan (TS-121 / ANC-501)Discontinued
  Major depressive disorder· V1B receptor Antagonist· Taisho Pharmaceutical Co., Ltd.
• Brilaroxazine (RP5063)Phase 3
  Schizophrenia· D2 Partial agonist· Reviva Pharmaceuticals Holdings, Inc.
• CentanafadineFiled (NDA)
  Attention-deficit/hyperactivity disorder· NET Reuptake inhibitor· Otsuka Pharmaceutical Co., Ltd.
• CN-105Phase 2
  Intracerebral hemorrhage· LRP1 Agonist· AegisCN LLC
• CYB003 (deupsilocin)Phase 3
  Major depressive disorder· 5-HT2A Agonist· Helus Pharma
• CYB004 (deuterated DMT)Phase 2
  Generalized anxiety disorder· 5-HT2A Agonist· Helus Pharma
• Darigabat (CVL-865)Discontinued
  Epilepsy· GABA-A receptor alpha-2 PAM· Cerevel Therapeutics Holdings, Inc.
• Dexmedetomidine sublingual film (BXCL501)Phase 3
  Agitation in Alzheimer's disease· alpha-2A adrenoceptor Agonist· BioXcel Therapeutics, Inc.
• Direclidine (NBI-1117568)Phase 3
  Schizophrenia· M4 Agonist· Neurocrine Biosciences, Inc.
• DT-101Phase 2
  Major depressive disorder· AMPA receptor PAM· Draig Therapeutics Ltd
• DT402Phase 2
  Autism spectrum disorder· SERT Releaser· Definium Therapeutics, Inc.
• EcopipamFiled (NDA)
  Tourette syndrome· D1 receptor Antagonist· Emalex Biosciences Inc.
• ELE-101 (intravenous psilocin benzoate)Phase 1/2
  Major depressive disorder· 5-HT2A Agonist· Beckley Psytech Limited
• Elpipodect (MK-8189)Discontinued
  Schizophrenia· PDE10A Inhibitor· Merck & Co., Inc.
• Elunetirom (ABX-002)Phase 2
  Bipolar depression· TRbeta Agonist· Autobahn Therapeutics, Inc.
• EMP-01 (oral R-MDMA)Phase 2
  Social anxiety disorder· SERT Releaser· EmpathBio, Inc.
• Emraclidine (CVL-231)Phase 2
  Schizophrenia· M4 PAM· Cerevel Therapeutics Holdings, Inc.
• EmrusolminPhase 2
  Multiple System Atrophy· Alpha-synuclein Modulator· Teva Pharmaceutical Industries Ltd.
• Enerisant (TS-091)Discontinued
  Narcolepsy· H3 receptor Inverse agonist· Taisho Pharmaceutical Co., Ltd.
• ENX-104Phase 1
  Major depressive disorder· D2 Antagonist· Engrail Therapeutics, Inc.
• Esmethadone (REL-1017)Discontinued
  Major depressive disorder· GluN2D Antagonist· Relmada Therapeutics, Inc.
• Fasedienol (PH94B)Phase 3
  Social anxiety disorder· Nasal chemosensory receptor neurons Agonist· Vistagen Therapeutics, Inc.
• ForvisirvatPhase 2/3
  Major depressive disorder· SIRT6 Activator· Sirtsei Pharmaceuticals, Inc.
• GlyphAllo (SPT-300)Phase 2
  Major depressive disorder· GABA-A receptor PAM· Seaport Therapeutics, Inc.
• IcalcaprantPhase 2
  Major depressive disorder· KOR Antagonist· Cerevel Therapeutics Holdings, Inc.
• Iclepertin (BI 425809)Discontinued
  Schizophrenia· GlyT1 Inhibitor· Boehringer Ingelheim International GmbH
• Iloperidone LAIPhase 3
  Schizophrenia· 5-HT2A Antagonist· Vanda Pharmaceuticals Inc.
• ITI-1284 (deulumateperone)Phase 2
  Alzheimer's disease· 5-HT2A Antagonist· Intra-Cellular Therapies, Inc.
• ItruvonePhase 2
  Major depressive disorder· Nasal chemosensory neuron receptor (uncharacterized) Unknown· Pherin Pharmaceuticals, Inc.
• JNJ-2056 (ACI-35.030)Phase 2
  Alzheimer's disease· Tau (pT217) Agonist· Johnson & Johnson
• KYN-5356Phase 2
  Schizophrenia· KAT-II Inhibitor· Mitsubishi Tanabe Pharma Corporation
• LB-102 (N-methylamisulpride)Phase 3
  Schizophrenia· D2 Antagonist· LB Pharmaceuticals Inc.
• Lenrispodun (ITI-214)Phase 2
  Parkinson's disease· PDE1B Inhibitor· Intra-Cellular Therapies, Inc.
• LHP588Phase 2
  Alzheimer's disease· Lysine-gingipain (Kgp) Inhibitor· Cortexyme, Inc. (now Quince Therapeutics, Inc.)
• LPCN 1154 (oral brexanolone)Phase 3
  Postpartum depression· GABA-A receptor PAM· Lipocine Inc.
• Lumateperone (ITI-007)Approved
  Schizophrenia· 5-HT2A Antagonist· Intra-Cellular Therapies, Inc.
• LUMRYZ (sodium oxybate extended-release)Phase 3
  Idiopathic Hypersomnia· GABA-B receptor Agonist· Alkermes plc
• Luvadaxistat (TAK-831)Discontinued
  Schizophrenia· DAAO Inhibitor· Neurocrine Biosciences, Inc.
• Luvesilocin (RE104)Phase 2
  Postpartum depression· 5-HT2A Agonist· Reunion Neuroscience Inc.
• LYBALVI (olanzapine/samidorphan)Phase 3
  Schizophrenia· D2 Antagonist· Alkermes plc
• Lysergide D-tartrate (MM120 / LSD)Phase 3
  Generalized anxiety disorder· 5-HT2A Partial agonist· Definium Therapeutics, Inc.
• Mebufotenin (inhaled 5-MeO-DMT, GH001)Phase 2
  Treatment-resistant depression· 5-HT2A Agonist· GH Research PLC
• Mefluleucine (NV-5138)Discontinued
  Treatment-resistant depression· mTORC1 Activator· Navitor Pharmaceuticals, Inc.
• Methylone (TSND-201)Phase 3
  Post-traumatic stress disorder· SERT Releaser· Transcend Therapeutics, Inc.
• Milsaperidone (VHX-896)Phase 3
  Major depressive disorder· 5-HT2A Antagonist· Vanda Pharmaceuticals Inc.
• MK-1167Phase 2
  Alzheimer's disease· alpha7 nAChR PAM· Merck & Co., Inc.
• MK-1942Discontinued
  Treatment-resistant depression· mGluR2 NAM· Merck & Co., Inc.
• MK-2214Phase 2
  Alzheimer's disease· Tau (pT217) Inhibitor· Merck & Co., Inc.
• ML-007C-MAPhase 2
  Schizophrenia· M1 Agonist· MapLight Therapeutics, Inc.
• MSP-1014Phase 2
  Major depressive disorder· 5-HT2A Agonist· Mindset Pharma Inc.
• Navacaprant (NMRA-140)Discontinued
  Major depressive disorder· KOR Antagonist· Neumora Therapeutics, Inc.
• NBI-1065890Phase 2
  Tardive Dyskinesia· VMAT2 Inhibitor· Neurocrine Biosciences, Inc.
• NBI-1070770Phase 2
  Major depressive disorder· GluN2B NAM· Neurocrine Biosciences, Inc.
• NBI-1117570Phase 2
  Schizophrenia· M4 Agonist· Neurocrine Biosciences, Inc.
• Nelivaptan (BH-200)Phase 2
  Major depressive disorder· V1B receptor Antagonist· Sanofi
• NMRA-511Phase 1
  Agitation in Alzheimer's disease· V1a receptor Antagonist· Neumora Therapeutics, Inc.
• NTX-1472Phase 2
  Social anxiety disorder· V1a receptor Antagonist· Hoffmann-La Roche
• Olanzapine extended-release injectable suspension (TEV-'749)Filed (NDA)
  Schizophrenia· D2 Antagonist· Teva Pharmaceutical Industries Ltd.
• Opakalim (BHV-7000)Phase 3
  Epilepsy· Kv7.2 Activator· Biohaven Ltd.
• OPC-64005Discontinued
  Major depressive disorder· SERT Reuptake inhibitor· Otsuka Pharmaceutical Co., Ltd.
• Osavampator (NBI-1065845)Phase 3
  Major depressive disorder· AMPA receptor (GluA1) PAM· Neurocrine Biosciences, Inc.
• OveporextonFiled (NDA)
  Narcolepsy· OX2R Agonist· Takeda Pharmaceutical Company Limited
• PosdinemabDiscontinued
  Alzheimer's disease· Tau (pT217) Inhibitor· Johnson & Johnson
• Psilocybin (COMP360)Phase 3
  Treatment-resistant depression· 5-HT2A Partial agonist· COMPASS Pathways plc
• RemlifanserinPhase 3
  Alzheimer's disease psychosis· 5-HT2A Inverse agonist· ACADIA Pharmaceuticals Inc.
• Roluperidone (MIN-101)Phase 3
  Schizophrenia· 5-HT2A Antagonist· Minerva Neurosciences, Inc.
• RopanicantPhase 2
  Major depressive disorder· alpha4beta2 nAChR Antagonist· Suven Life Sciences Limited
• Seltorexant (JNJ-42847922)Phase 3
  Major depressive disorder· OX2R Antagonist· Johnson & Johnson
• SepranolonePhase 2
  Tourette syndrome· GABA-A receptor Antagonist· Relmada Therapeutics, Inc.
• Solriamfetol (Sunosi)Phase 3
  Major depressive disorder· NET Reuptake inhibitor· Axsome Therapeutics, Inc.
• TAK-360Phase 2
  Narcolepsy· OX2 receptor Agonist· Takeda Pharmaceutical Company Limited
• TavapadonFiled (NDA)
  Parkinson's disease· D1 receptor Partial agonist· Cerevel Therapeutics Holdings, Inc.
• TNX-102 SL (cyclobenzaprine HCl sublingual)Approved
  Fibromyalgia· H1 receptor Antagonist· Tonix Pharmaceuticals Holding Corp.
• TNX-1900Discontinued
  Migraine· Oxytocin receptor Agonist· Tonix Pharmaceuticals Holding Corp.
• Troriluzole (BHV-4157)Discontinued
  Obsessive-compulsive disorder· EAAT2 Modulator· Biohaven Ltd.
• TS-161Discontinued
  Treatment-resistant depression· mGlu2 Antagonist· Taisho Pharmaceutical Co., Ltd.
• Ulefnersen (ION363)Phase 3
  Amyotrophic lateral sclerosis· FUS Inhibitor· Ionis Pharmaceuticals, Inc.
• Ulotaront (SEP-363856)Phase 2/3
  Generalized anxiety disorder· TAAR1 Agonist· Otsuka Pharmaceutical Co., Ltd.
• VLS-01Phase 2
  Treatment-resistant depression· 5-HT2A Agonist· Atai Beckley N.V. (AtaiBeckley)
• Vornorexant (TS-142)Approved
  Insomnia· OX2 receptor Antagonist· Taisho Pharmaceutical Co., Ltd.
• VQW-765Phase 3
  Social anxiety disorder· alpha7 nAChR Partial agonist· Vanda Pharmaceuticals Inc.
• Zalsupindole (DLX-001)Phase 1
  Major depressive disorder· 5-HT2A Partial agonist· Delix Therapeutics, Inc.
• Zelquistinel (GATE-251)Phase 2
  Major depressive disorder· GluN2B PAM· Syndeio Biosciences, Inc.